We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Sanofi Snags Kadmon Pharmaceuticals and Its First-in-Class Anti-Rejection Molecule in $1.9 Billion Deal
Sanofi Snags Kadmon Pharmaceuticals and Its First-in-Class Anti-Rejection Molecule in $1.9 Billion Deal
Sanofi has dropped $1.9 billion to acquire New York-based Kadmon Pharmaceuticals and its first-in-class oral kinase inhibitor, Rezurock (belumosudil), approved in July to treat chronic graft-vs.-host disease (cGVHD).